TY  - GEN
AU  - Cheng,H
AU  - Ballman,K
AU  - Vassilakopoulou,M
AU  - Dueck,A C
AU  - Reinholz,M M
AU  - Tenner,K
AU  - Gralow,J
AU  - Hudis,C
AU  - Davidson,N E
AU  - Fountzilas,G
AU  - McCullough,A E
AU  - Chen,B
AU  - Psyrri,A
AU  - Rimm,D L
AU  - Perez,E A
TI  - EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial
SN  - 1532-1827
PY  - 2014///1104
KW  - Antibodies, Monoclonal, Humanized
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Biomarkers, Tumor
KW  - analysis
KW  - Breast Neoplasms
KW  - chemistry
KW  - Disease-Free Survival
KW  - ErbB Receptors
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Middle Aged
KW  - Receptor, ErbB-2
KW  - Survival Rate
KW  - Tissue Array Analysis
KW  - Trastuzumab
N1  - Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
UR  - https://doi.org/10.1038/bjc.2014.442
ER  -